Furosemide Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg/mL 40 mg/4 mL & 80mg/8ml
Reference Brands: Lasix® (US & EU)
Category:
Nephrology
Furosemide Injection is a diuretic used to treat edema and fluid retention in patients with chronic kidney disease (CKD), heart failure, and liver cirrhosis. Available in strengths like 10 mg/mL and 40 mg/4 mL, it helps regulate fluid balance and alleviate symptoms of fluid overload.
Furosemide is available in Injection
and strengths such as 10 mg/mL 40 mg/4 mL & 80mg/8ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Furosemide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Furosemide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Furosemide Injection is a widely used diuretic in nephrology, primarily for managing edema and fluid retention in patients with chronic kidney disease (CKD), heart failure, and liver cirrhosis. Available in 10 mg/mL, 40 mg/4 mL, and 80 mg/8 mL strengths, Furosemide helps regulate fluid balance and alleviate symptoms of fluid overload. For B2B distribution in the US and EU, Furosemide is supplied by well-known brands like Lasix®, Hospira, and Sandoz. Its injectable form allows for rapid administration in clinical and hospital settings, making it a crucial treatment option for nephrology and cardiology care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing